Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Compounds for the treatment of Leishmaniasis and other diseases caused by trypanosomes

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOES20201216002
Publicado:
29/12/2020
Caducidad:
30/12/2021
Resumen:
Researchers from two Spanish Universities have developed a series of useful compounds for the treatment of Leishmaniasis and other diseases caused by parasites of the Trypanosomatidae family that represent a potential alternative to the usual treatments. The researchers are looking for partners from the pharmaceutical industry interested in licensing these patented compounds.

Details

Tittle:
Compounds for the treatment of Leishmaniasis and other diseases caused by trypanosomes
Summary:
Researchers from two Spanish Universities have developed a series of useful compounds for the treatment of Leishmaniasis and other diseases caused by parasites of the Trypanosomatidae family that represent a potential alternative to the usual treatments. The researchers are looking for partners from the pharmaceutical industry interested in licensing these patented compounds.
Description:
Leishmaniasis is an infectious and parasitic disease, classified as a "neglected tropical disease" by the WHO, which affects millions of people every year and exists mainly in developing countries. Despite its relevance and incidence, there is still no effective vaccine or effective treatment to combat it. The drugs currently used have some disadvantages such as high toxicity, difficulty in administration, generation of resistance, and high cost. The global set of these problems, also common to other diseases caused by parasites of the Trypanosomatidae family, such as Chagas disease, imply the need for the development of new, more effective treatments that represent an alternative to the usual ones.

A research group from two Spanish Universities has developed a series of useful compounds for the treatment of Leishmaniasis and other diseases caused by parasites of the Trypanosomatidae family. They have observed antiparasitic activity in a series of aromatic heterocyclic compounds, thus enabling their use as a treatment against diseases caused by protozoa of the Trypanosomatidae family, mainly Leishmaniasis, and within these, visceral Leishmaniasis, cutaneous Leishmaniasis or mucocutaneous Leishmaniasis. Compounds proposed in this invention have shown antiparasitic activity against three strains of the genus Leishmania that are the main causes of Leishmaniasis.

Moreover, according to the results of the assays carried out, these compounds have lower toxicity than the toxicity associated with the use of the reference commercial treatments.

The research group is looking for partners interested in licensing these patented compounds.
Advantages and Innovations:
- Greater antiparasitic activity. The antiparasitic activity against the Leishmania strains tested is, in almost all of the proposed compounds, higher than said activity performed by the reference commercial treatment.

- Low toxicity. Current commercial treatments to combat these diseases are highly toxic. These compounds show lower toxicity than that observed in them.

- Affection of the parasite without inhibiting the human enzyme. The compounds of the invention can inhibit the parasite enzyme with an IC50 value lower than that necessary to significantly inhibit the human erythrocyte enzyme.

- Possibility of industrial scaling. Due to the simplicity of the proposed synthesis method and the ease of scaling it for industrial production.
Stage of Development:
Under development/lab tested
IPs:
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
Spanish patent applied and PCT pending

Partner sought

Type and Role of Partner Sought:
The research group is looking for companies involved in the treatment of parasitic diseases such as leishmaniasis and / or Chagas disease, in order to reach a license agreement.

Client

Type and Size of Client:
University
Already Engaged in Trans-National Cooperation:
No
Languages Spoken:
English
Spanish

Keywords

Technology Keywords:
06001001 Bioestadística, epidemiología
06001015 Productos farmacéuticos / medicamentos
06001006 Vacunas humanas
06001018 Virus, virología / antibióticos / bacteriología